Why did Cooper Companies (COO) stock move recently?

On 9/10/2026, Cooper Companies moved -14.1% — CooperCompanies fell sharply after fiscal Q3 revenue of $1.066 billion came in below the roughly $1.10 billion consensus and the company cut full-year adjusted EPS guidance to $4.51-$4.55. Its board also concluded the strategic review by deciding to retain CooperSurgical rather than sell it. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Cooper Companies (COO) overvalued or fairly valued?

MarketChacha shows Cooper Companies's valuation in context — a trailing P/E of about 19.8, a forward P/E of about 12.4, a price-to-book of about 1.3 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Cooper Companies's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.99×) from reported figures — education, not a rating.

What is Cooper Companies's revenue?

Cooper Companies reported revenue of $4.1B for FY2025, with net profit of $374.9M, per official filings.

What is the share price of Cooper Companies (COO)?

Cooper Companies last traded at $59.06 (+1.5% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Cooper Companies

COO · NYSE · Healthcare · United States

Snapshot

TickerCOO

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees15,000

HeadquartersSan Ramon, United States

Websitewww.coopercos.com

Filings tracked15

About Cooper Companies

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage. This segment offers Paragard, a hormone-free intrauterine device; and fertility consumables and equipment, donor gamete services, and genomic services, including genetic testing. The company sells its products to distributors, group purchasing organizations, eye care and health care professionals, including independent practices, corporate retailers, hospitals and clinics, and authorized resellers. The Cooper Companies, Inc. was founded in 1958 and is headquartered in San Ramon, California.

Who owns it

Insiders0.6%
Institutions99.4%
Public & other0.0%

972 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.7.90%
Vanguard Capital Management LLC6.71%
State Street Corporation4.68%
Vanguard Portfolio Management LLC4.56%
T. Rowe Price Investment Management, Inc.3.91%
Browning West Lp3.78%
Price (T.Rowe) Associates Inc2.93%
Kayne Anderson Rudnick Investment Management LLC2.86%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Latest ROE of 4.6% is on the low side — the business earns a modest return on shareholder capital.

Cash conversion1.99×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend8.2% → 9.2%

Margin has held broadly steady over the period — stable profitability.

Return on equity4.6%

Latest ROE of 4.6% is on the low side — the business earns a modest return on shareholder capital.

Growth qualityrev 7% · PAT 13%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.1B · EPS 1.10

Est. earnings growth +0.3%

Next fiscal year

Rev $4.4B · EPS 4.69

Est. earnings growth +3.6%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$4.1B

Net margin

9.2%

ROE

4.6%

Revenue CAGR (2y)

+6.7%

Profit CAGR (2y)

+12.9%

EPS (FY2025)

1.87

Net profit (FY2025)

$374.9M

Ask MarketChacha about COO

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Sep 10, 2026
CooperCompanies fell sharply after fiscal Q3 revenue of $1.066 billion came in below the roughly $1.10 billion consensus and the company cut full-year adjusted EPS guidance to $4.51-$4.55. Its board also concluded the strategic review by deciding to retain CooperSurgical rather than sell it.
source 1 ↗· confidence: high
Aug 25, 2026
COO fell 3.64% with the broader healthcare sector and equity markets amid rising Treasury yields and inflation concerns; no company-specific catalyst appears in today's coverage or recent filings.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$4.1B	$374.9M	1.87	9.2%	4.6%
FY2024	$3.9B	$392.3M	1.96	10.1%	4.9%
FY2023	$3.6B	$294.2M	1.48	8.2%	3.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q3	$1.1B	$432.8M	2.24	40.6%
2026Q2	$1.1B	$-77.9M	-0.40	-7.2%
2026Q1	$1.0B	$130.8M	0.66	12.8%
2025Q3	$1.1B	$98.3M	0.49	9.3%
2025Q2	$1.0B	$87.7M	0.44	8.7%
2025Q1	$964.7M	$104.3M	0.52	10.8%
2024Q3	$1.0B	$104.7M	0.52	10.4%
2024Q2	$942.6M	$88.9M	0.44	9.4%
2024Q1	$931.6M	$81.2M	0.41	8.7%
2023Q3	$930.2M	$85.3M	0.43	9.2%
2023Q2	$877.4M	$39.8M	0.20	4.5%
2023Q1	$858.5M	$84.6M	0.43	9.9%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Results of operations, Other events, Exhibits
SEC9/9/2026material
10-Q filing
SEC9/9/2026
10-Q filing
SEC6/5/2026
8-K — Results of operations, Other events, Exhibits
SEC6/4/2026material
8-K — Executive/director change
SEC5/4/2026material
8-K — Shareholder vote results
SEC4/8/2026material
10-Q filing
SEC3/6/2026
8-K — Results of operations, Exhibits
SEC3/5/2026material
8-K — Material agreement, Exhibits
SEC2/4/2026material

2025

8-K — Material agreement, Executive/director change, Reg FD disclosure, Exhibits
SEC12/23/2025material
8-K — Executive/director change
SEC12/12/2025material
10-K filing
SEC12/5/2025
8-K — Results of operations, Executive/director change, Reg FD disclosure, Exhibits
SEC12/4/2025material
10-Q filing
SEC8/28/2025
8-K — Results of operations, Exhibits
SEC8/27/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.